HER3 PET Imaging: <sup>68</sup>Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to <sup>89</sup>Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

HER3 PET Imaging: <sup>68</sup>Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to <sup>89</sup>Zr-Labeled Antibody and Antibody-Fragment-Based Tracers

HER3 (human epidermal growth factor receptor type 3) is a challenging target for diagnostic radionuclide molecular imaging due to the relatively modest overexpression in tumors and substantial expression in healthy organs. In this study, we compared four HER3-targeting PET tracers based on different...

Full description

Bibliographic Details
Main Authors:	Sara S. Rinne, Charles Dahlsson Leitao, Ayman Abouzayed, Anzhelika Vorobyeva, Vladimir Tolmachev, Stefan Ståhl, John Löfblom, Anna Orlova
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Series:	Cancers
Subjects:	HER3 PET seribantumab MM-121 zirconium-89 gallium-68
Online Access:	https://www.mdpi.com/2072-6694/13/19/4791

Similar Items

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
by: Charles Dahlsson Leitao, et al.
Published: (2020-06-01)

In Vitro and In Vivo Characterization of <sup>89</sup>Zirconium-Labeled Lintuzumab Molecule
by: Kevin J. H. Allen, et al.
Published: (2022-10-01)

Production and Semi-Automated Processing of <sup>89</sup>Zr Using a Commercially Available TRASIS MiniAiO Module
by: Vijay Gaja, et al.
Published: (2020-06-01)

<sup>89</sup>Zr-Labeled AR20.5: A MUC1-Targeting ImmunoPET Probe
by: Kimberly Fung, et al.
Published: (2020-05-01)

A Semi Rigid Novel Hydroxamate AMPED-Based Ligand for <sup>89</sup>Zr PET Imaging
by: Lisa Russelli, et al.
Published: (2021-09-01)

From Bench to Bedside: Patient-Oriented Radiopharmaceutical Development in Nuclear Medicine Based on the Example of [<sup>89</sup>Zr]Zr-PSMA-DFO
by: Klaus Schomäcker, et al.
Published: (2023-12-01)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody<sup>®</sup> Molecules <sup>177</sup>Lu-ABY-271 and <sup>177</sup>Lu-ABY-027: Impact of DOTA Position on ABD Domain
by: Yongsheng Liu, et al.
Published: (2021-06-01)

Preclinical PET and MR Evaluation of <sup>89</sup>Zr- and <sup>68</sup>Ga-Labeled Nanodiamonds in Mice over Different Time Scales
by: Gordon Winter, et al.
Published: (2022-12-01)

Comparative Evaluation of Novel <sup>177</sup>Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
by: Hanna Tano, et al.
Published: (2021-01-01)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule <sup>188</sup>Re-ZHER2:41071
by: Yongsheng Liu, et al.
Published: (2022-05-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

Preclinical Evaluation of a New Format of <sup>68</sup>Ga- and <sup>111</sup>In-Labeled Affibody Molecule Z<sub>IGF-1R:4551</sub> for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT
by: Yongsheng Liu, et al.
Published: (2022-07-01)

In Vivo PET Imaging of Monocytes Labeled with [<sup>89</sup>Zr]Zr-PLGA-NH<sub>2</sub> Nanoparticles in Tumor and <i>Staphylococcus aureus</i> Infection Models
by: Massis Krekorian, et al.
Published: (2021-10-01)

Preclinical Evaluation of <sup>99m</sup>Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
by: Maryam Oroujeni, et al.
Published: (2021-03-01)

Quantitative Biodistribution and Pharmacokinetics Study of GMP-Grade Exosomes Labeled with <sup>89</sup>Zr Radioisotope in Mice and Rats
by: Hojun Choi, et al.
Published: (2022-05-01)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
by: Mohamed Altai, et al.
Published: (2018-10-01)

Current Perspectives on <sup>89</sup>Zr-PET Imaging
by: Joon-Kee Yoon, et al.
Published: (2020-06-01)

Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
by: Helen Damerow, et al.
Published: (2022-10-01)

Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology
by: Yvonne W.S. Jauw, et al.
Published: (2016-05-01)

Biodistribution of Mesenchymal Stromal Cells Labeled with [<sup>89</sup>Zr]Zr-Oxine in Local Radiation Injuries in Laboratory Animals
by: Tatiana A. Astrelina, et al.
Published: (2023-10-01)

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
by: Maryke Kahts, et al.
Published: (2023-11-01)

In vivo amyloid-β imaging in the APPPS1-21 transgenic mouse model with a 89Zr- labeled monoclonal antibody.
by: Ann-Marie eWaldron, et al.
Published: (2016-03-01)

Side-by-Side Comparison of Five Chelators for <sup>89</sup>Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability
by: Helen Damerow, et al.
Published: (2021-12-01)

[<sup>89</sup>Zr]-Atezolizumab-PET Imaging Reveals Longitudinal Alterations in PDL1 during Therapy in TNBC Preclinical Models
by: Adriana V. F. Massicano, et al.
Published: (2023-05-01)

Evaluation of Chelator-to-Antibody Ratio on Development of <sup>89</sup>Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor
by: Shih-Chuan Tsai, et al.
Published: (2023-12-01)

3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body <sup>18</sup>F-Fluorodeoxyglucose and <sup>89</sup>Zr-Rituximab PET Scans
by: Bart M. de Vries, et al.
Published: (2022-02-01)

Direct In Vivo Comparison of <sup>99m</sup>Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
by: Vladimir Tolmachev, et al.
Published: (2022-12-01)

<sup>89</sup>Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
by: Iris H. C. Miedema, et al.
Published: (2023-11-01)

89Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs
by: Kevin Wyszatko, et al.
Published: (2024-03-01)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of <sup>89</sup>Zr Immune-PET Tracers
by: Ryota Imura, et al.
Published: (2021-08-01)

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with <sup>99m</sup>Tc for Radionuclide Imaging of HER2 Expression in Cancer
by: Mariia Larkina, et al.
Published: (2022-11-01)

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
by: Tianqi Xu, et al.
Published: (2023-02-01)

<sup>89</sup>Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo
by: Elahe Alizadeh, et al.
Published: (2021-02-01)

Preclinical Evaluation of <sup>99m</sup>Tc-Labeled GRPR Antagonists maSSS/SES-PEG<sub>2</sub>-RM26 for Imaging of Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2021-01-01)

Recent Advances in Zirconium-89 Chelator Development
by: Nikunj B. Bhatt, et al.
Published: (2018-03-01)

Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI
by: Laura M. Lechermann, et al.
Published: (2020-07-01)

α-Zirconium(IV) Phosphate: Static Study of <sup>225</sup>Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using <sup>nat</sup>Eu as a Model System for <sup>225</sup>Ac
by: Lukáš Ondrák, et al.
Published: (2023-08-01)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope <sup>66</sup>Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
by: Maryam Oroujeni, et al.
Published: (2021-02-01)

Radiolabelling of Polyclonally Expanded Human Regulatory T Cells (Treg) with <sup>89</sup>Zr-oxine for Medium-Term <i>In Vivo</i> Cell Tracking
by: Jacinta Jacob, et al.
Published: (2023-02-01)

A Theranostic Approach to Imaging and Treating Melanoma with <sup>203</sup>Pb/<sup>212</sup>Pb-Labeled Antibody Targeting Melanin
by: Rubin Jiao, et al.
Published: (2023-07-01)